Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

NCT03465540 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03465540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03465540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Terminated
Start date
August 17, 2018
Completion date
July 25, 2019
Enrollment
24 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, aml, mds, multiple myeloma, myelodysplastic syndrome, nhl, non-hodgkins lymphoma